The Journal of Immunology, Vol 149, Issue 8 2634-2640, Copyright © 1992 by American Association of Immunologists

ARTICLES

DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DR beta 1 alleles

J Sidney, C Oseroff, S Southwood, M Wall, G Ishioka, F Koning and A Sette
Cytel, San Diego, CA 92121.

The DR3-restricted peptide, MT 65 kDa 3-13, was used to develop a DR3- specific binding assay. The binding activity detected was strictly pH- dependent, in that it was optimal in the pH 4 to 5 range, and no activity was detected at neutral pH. By means of affinity chromatography purifications and the use of DR3-transfected fibroblasts, it was shown that no cross-reactivity exists at the level of DR52a molecules, thus allowing use of only partially purified DR3/DR52a mixtures in high throughput binding assays. The immunologic relevance of the assay established was also verified by examining the correlation between DR3 restriction and binding for a panel of DR- restricted peptides. When the structural requirements for peptide DR3 interactions were further examined by using panels of analogues of two different epitopes (Myo 132-151 and TT 830-843), it was found that DR3 molecules recognized a peptide motif distinct from the one recognized by the other major DR beta 1 alleles.

This article has been cited by other articles:

				X.-F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillere Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients J. Immunol., July 1, 2008; 181(1): 431 - 439. [Abstract] [Full Text] [PDF]

				H. Inaba, W. Martin, A. S. De Groot, S. Qin, and L. J. De Groot Thyrotropin Receptor Epitopes and Their Relation to Histocompatibility Leukocyte Antigen-DR Molecules in Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2286 - 2294. [Abstract] [Full Text] [PDF]

				I. G. Ovsyannikova, K. L. Johnson, D. C. Muddiman, R. A. Vierkant, and G. A. Poland Identification and Characterization of Novel, Naturally Processed Measles Virus Class II HLA-DRB1 Peptides J. Virol., January 1, 2004; 78(1): 42 - 51. [Abstract] [Full Text] [PDF]

				J. Sidney, M.-F. del Guercio, S. Southwood, and A. Sette The HLA Molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 Share an Extensive Overlap in Peptide Binding Specificity J. Immunol., November 1, 2002; 169(9): 5098 - 5108. [Abstract] [Full Text] [PDF]

				R. Raju, E. G. Spack, and C. S. David Acetylcholine Receptor Peptide Recognition in HLA DR3-Transgenic Mice: In Vivo Responses Correlate with MHC-Peptide Binding J. Immunol., July 15, 2001; 167(2): 1118 - 1124. [Abstract] [Full Text] [PDF]

				Y. Sawai and L. J. DeGroot Binding of Human Thyrotropin Receptor Peptides to a Graves' Disease-Predisposing Human Leukocyte Antigen Class II Molecule J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1176 - 1179. [Abstract] [Full Text]

				N. Nagvekar, L. Corlett, L. W. Jacobson, H. Matsuo, R. Chalkley, P. C. Driscoll, S. Deshpande, E. G. Spack, and N. Willcox Scanning a DRB3*0101 (DR52a)-Restricted Epitope Cross-Presented by DR3: Overlapping Natural and Artificial Determinants in the Human Acetylcholine Receptor J. Immunol., April 1, 1999; 162(7): 4079 - 4087. [Abstract] [Full Text] [PDF]

				P. M. Lavoie, J. Thibodeau, I. Cloutier, R. Busch, and R.-P. Sekaly Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM PNAS, June 24, 1997; 94(13): 6892 - 6897. [Abstract] [Full Text] [PDF]

				A Sette, S Ceman, R. Kubo, K Sakaguchi, E Appella, D. Hunt, T. Davis, H Michel, J Shabanowitz, R Rudersdorf, et al. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant Science, December 11, 1992; 258(5089): 1801 - 1804. [Abstract] [PDF]